Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7, the final stage of testing, the World Health Organization said on Thursday.
A second vaccine, developed by GlaxoSmithKline will be tested "in a sequential study, as supply becomes available", the WHO said.